Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 27, 2016
Zacks Investment Research has upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Hold in a statement released on Tuesday September 27, 2016.
On 9/26/2016, Leerink Swann released a statement for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) bumped up the target price from $210.00 to $211.00 that suggested an upside of 0.68%.
Boasting a price of $124.51, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded 1.08% higher on the day. With the last stock price close down -7.10% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Alexion Pharmaceuticals, Inc. has recorded a 50-day average of $130.45 and a two hundred day average of $135.48. Volume of trade was down over the average, with 1,055,317 shares of ALXN changing hands under the typical 1,628,260
With a total market value of $0, Alexion Pharmaceuticals, Inc. has price-earnings ratio of 316.23 with a one year low of $110.56 and a one year high of $193.45 .
A total of 18 equity analysts have released a ratings update on ALXN. Seven equity analysts rating the company a strong buy, six equity analysts rating the company a buy, seven equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $187.61.
Brief Synopsis About Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.